<DOC>
	<DOCNO>NCT02298985</DOCNO>
	<brief_summary>Schizophrenia still remain one disabling disorder despite progress treatment mental disturbance . Ten thirty percent patient little benefit treatment kind antipsychotic use adequate dosage duration . Treatment patient remain persistent public health problem since medication-resistant patient often highly symptomatic . Curcumin one main curcuminoids isolate perennial herb . It possess variety pharmacological activity , include anti-inflammatory , antiproliferative , antioxidant , neuroprotective effect cross blood-brain barrier . The purpose suggest study examine efficacy curcumin add-on conventional antipsychotic psychopharmacotherapy chronic schizophrenia patient .</brief_summary>
	<brief_title>Curcumin Addition Antipsychotic Treatment Chronic Schizophrenia Patients</brief_title>
	<detailed_description>Study Design This 24-week , randomize , double-blind , placebo-controlled investigation 40 chronic schizophrenia patient . Participants Forty patient draw patient population Be'er Sheva Mental Health Center . Recruitment period last 2 year . Patients require primary diagnosis chronic schizophrenia define DSM-IV predominantly persistent negative sign . The study commence approval local Institutional Ethics Review Board ( `` Helsinki Committee '' ) . Only willing subject able provide write informed consent , receive comprehensive explanation study procedure , include study . Confidentially ensure mean number cod system , complete research form store secure area . Procedure Patients continue receive regular antipsychotic medication . The dose kept constant least 3 month prior entry throughout study period . Curcumin provide Curcumin Forte Â® ( Solgar Israel SupHerb ) . Circumin capsule supply 1000 mg soft gelatin capsule three daily oral administration meal . At entry patient receive curcuma capsule ( 3000 mg/day , three capsule ) placebo identical capsule randomize , double blind mode 24 week : 20 patient receive curcumin , 20 patient - placebo . Participants assess baseline 4 , 8 , 12 , 16 24 week treatment . In case treatment discontinuation 24-week trial , patient follow end study period . Outcome variable evaluate score severity symptom ( positive , negative , etc . ) , side effect . In addition , liver function test blood cell count monitor baseline study . For analyze result , within-subject pre- post-treatment response would subject statistical procedure evaluate whether curcumin ameliorate persistent negative symptom schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Age 1860 year , male female DSMIV criterion schizophrenia . Ability willingness sign inform consent participation study SANS ( Scale Negative Symptoms Schizophrenia ) &gt; 30 point Fixed antipsychotic dosage least 3 month Steady mental state patient least 3 month Current substance use disorder except nicotine dependence Regular use NSAID ( nonsteroidal antiinflammatory drug ) Cancer history Untreated severe hypertension Poorly control diabetes mellitus Type I Type II Chronic liver &amp; gallbladder disease Recent GERD ( Gastroesophageal Reflux Disorder ) Neurological disorder : epilepsy , stroke Hamilton Depression Scale Hamilton Depression Rating Scale ( HAMD17 item ) &gt; 24 point Patients known hypersensitivity curcumin Pregnant woman woman intend become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>curcumin ; schizophrenia ; neuroprotection</keyword>
</DOC>